目的研究抗感染重组合异种骨(anti-infective reconstituted bone xenograft,ARBX)对感染性骨缺损的治疗作用。方法于2011年1月至2011年10月,32只新西兰种成年兔随机分为四组,每组8只,每只兔子胫骨近端做成大小为1.0cm×2.0cm×...目的研究抗感染重组合异种骨(anti-infective reconstituted bone xenograft,ARBX)对感染性骨缺损的治疗作用。方法于2011年1月至2011年10月,32只新西兰种成年兔随机分为四组,每组8只,每只兔子胫骨近端做成大小为1.0cm×2.0cm×1.0cm的矩形骨缺损模型,注入金葡球菌,2周后再次手术行病灶情除,分别在骨缺损中植入ARBX(ARBX组)、植入重组合异种骨(reconstituted bone xenograft,RBX)并肌注庆大霉索(RBX+全身用药组),单纯植入RBX(RBX组)以及不植骨(不植骨组)。术后8周对缺损修复情况行大体解剖学、放射学、组织学、细菌学检查。结果①ARBX组细菌计数及改良X线Norden感染分值极低,明显小于其他各组(P<0.01),其解剖学和组织学观察均无明显的骨髓炎表现;②RBX+全身用药组与RBX组的细菌计数,改良X线Norden感染分值均较高,明显大于ARBX组及不植骨组(P<0.01);其解剖学和组织学均显示出严重的感染表现。结论①在病灶清除后,ARBX一期植入能有效治疗感染性骨缺损;②在全身用药或不用药条件下,一期植入RBX反而会加重感染。展开更多
Hepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapies have dominated over the past two decades. However, the overall response rates remain suboptimal. Thanks to the tre...Hepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapies have dominated over the past two decades. However, the overall response rates remain suboptimal. Thanks to the tremendous effort from both academia and industry, two serine protease inhibitors telaprevir and boceprevir for treating chronic hepatitis C have finally reached the clinic. Although these compounds are only approved for combination use with interferon and ribavirin in genotype 1 HCV infected chronic patients, the management of HCV patients however is now evolving incredibly. Here, we overviewed a series of landmark studies, regarding the clinical development of telaprevir and boceprevir. We discussed the mechanism-of-action of telaprevir/boceprevir and their potential application in HCV-positive liver transplantation patients. We further emphasized some emerging concerns with perspective of further development in this field.展开更多
There is an urgent need for new antifungal agents to treat or combat fungal infection in humans and plants.Antifungal nucleoside antibiotics are an important family of natural products with distinctive structural feat...There is an urgent need for new antifungal agents to treat or combat fungal infection in humans and plants.Antifungal nucleoside antibiotics are an important family of natural products with distinctive structural features.Understanding their biosynthetic machinery is of great importance for the improvement of antibiotics titers.More importantly,it is a requisite for combinatorial biosynthesis to create hybrid nucleoside antibiotics.We herein focus on findings on the natural and designed biosynthesis of this important family of nucleoside antibiotics.展开更多
文摘目的研究抗感染重组合异种骨(anti-infective reconstituted bone xenograft,ARBX)对感染性骨缺损的治疗作用。方法于2011年1月至2011年10月,32只新西兰种成年兔随机分为四组,每组8只,每只兔子胫骨近端做成大小为1.0cm×2.0cm×1.0cm的矩形骨缺损模型,注入金葡球菌,2周后再次手术行病灶情除,分别在骨缺损中植入ARBX(ARBX组)、植入重组合异种骨(reconstituted bone xenograft,RBX)并肌注庆大霉索(RBX+全身用药组),单纯植入RBX(RBX组)以及不植骨(不植骨组)。术后8周对缺损修复情况行大体解剖学、放射学、组织学、细菌学检查。结果①ARBX组细菌计数及改良X线Norden感染分值极低,明显小于其他各组(P<0.01),其解剖学和组织学观察均无明显的骨髓炎表现;②RBX+全身用药组与RBX组的细菌计数,改良X线Norden感染分值均较高,明显大于ARBX组及不植骨组(P<0.01);其解剖学和组织学均显示出严重的感染表现。结论①在病灶清除后,ARBX一期植入能有效治疗感染性骨缺损;②在全身用药或不用药条件下,一期植入RBX反而会加重感染。
基金Supported by Foundation for Liver and Gastrointestinal Research (SLO)The Netherlands Organisation for Scientific Research (NWO), No. VENI-grant 916-13-032 (to Pan Q)
文摘Hepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapies have dominated over the past two decades. However, the overall response rates remain suboptimal. Thanks to the tremendous effort from both academia and industry, two serine protease inhibitors telaprevir and boceprevir for treating chronic hepatitis C have finally reached the clinic. Although these compounds are only approved for combination use with interferon and ribavirin in genotype 1 HCV infected chronic patients, the management of HCV patients however is now evolving incredibly. Here, we overviewed a series of landmark studies, regarding the clinical development of telaprevir and boceprevir. We discussed the mechanism-of-action of telaprevir/boceprevir and their potential application in HCV-positive liver transplantation patients. We further emphasized some emerging concerns with perspective of further development in this field.
基金supported by grants from the Ministry of Science and Technology of China(2013CB 734001)the National Natural Science Foundation of China(31470206 and 31571281)
文摘There is an urgent need for new antifungal agents to treat or combat fungal infection in humans and plants.Antifungal nucleoside antibiotics are an important family of natural products with distinctive structural features.Understanding their biosynthetic machinery is of great importance for the improvement of antibiotics titers.More importantly,it is a requisite for combinatorial biosynthesis to create hybrid nucleoside antibiotics.We herein focus on findings on the natural and designed biosynthesis of this important family of nucleoside antibiotics.
